Expertise in
8
conditions

Dr. Joseph Muenzer

Pediatrics
101 Manning Dr, 
Chapel Hill, NC 
Accepting New Patients
Expertise in
8
conditions
101 Manning Dr, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Muenzer is a Pediatrics provider in Chapel Hill, North Carolina. Dr. Muenzer is highly rated in 8 conditions, according to our data. His top areas of expertise are Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), and Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A). Dr. Muenzer is currently accepting new patients.

His clinical research consists of co-authoring 63 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatrics
Licenses
Pediatrics in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

101 Manning Dr, Chapel Hill, NC 27599

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: DNL310
Study Phase: Phase 1/Phase 2
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
Enrollment Status: Completed
Publish Date: June 10, 2024
Intervention Type: Other
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
Enrollment Status: Terminated
Publish Date: October 25, 2022
Intervention Type: Biological
Study Drug: SB-913
Study Phase: Phase 1/Phase 2
A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Enrollment Status: Completed
Publish Date: June 28, 2021
Intervention Type: Drug, Other
Study Phase: Phase 1/Phase 2
A Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System Involvement and Who Are Currently Receiving Treatment With Elaprase®
A Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System Involvement and Who Are Currently Receiving Treatment With Elaprase®
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Other, Behavioral
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

63 Total Publications

Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses.
Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses.
Journal: Molecular genetics and metabolism
Published: June 25, 2024
Similar Doctors
Expertise in
11
conditions
Dr. Priya S. Kishnani
Pediatrics
Expertise in
11
conditions
Dr. Priya S. Kishnani
Pediatrics

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (9.5 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Priya Kishnani is a Pediatrics provider in Durham, North Carolina. Dr. Kishnani is highly rated in 11 conditions, according to our data. Her top areas of expertise are Pompe Disease, Glycogen Storage Disease Type 3, Glycogen Storage Disease Type 9, Hypophosphatasia (HPP), and Splenectomy. Dr. Kishnani is currently accepting new patients.

Expertise in
10
conditions
Dr. Matthew M. Laughon
Pediatrics
Expertise in
10
conditions
Dr. Matthew M. Laughon
Pediatrics
101 Manning Dr, 
Chapel Hill, NC 
 (0.1 mi)
919-966-8596
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Laughon is a Pediatrics provider in Chapel Hill, North Carolina. Dr. Laughon is highly rated in 10 conditions, according to our data. His top areas of expertise are Premature Infant, Bronchopulmonary Dysplasia, High Blood Pressure in Infants, and Intraventricular Hemorrhage of the Newborn. Dr. Laughon is currently accepting new patients.

Expertise in
8
conditions
Dr. Rasheed A. Gbadegesin
Pediatrics | Nephrology
Expertise in
8
conditions
Dr. Rasheed A. Gbadegesin
Pediatrics | Nephrology

Duke Health Integrated Practice Inc

2351 Erwin Rd, 
Durham, NC 
 (9.5 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rasheed Gbadegesin is a Pediatrics specialist and a Nephrologist in Durham, North Carolina. Dr. Gbadegesin is highly rated in 8 conditions, according to our data. His top areas of expertise are Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Minimal Change Disease, Glomerulonephritis, and Kidney Transplant. Dr. Gbadegesin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Muenzer's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile